Studies have shown that active fund managers routinely underperform the S&P500 index*​

Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS)

TARS Stock Predictions and Ratings

WSX Rating:
STRONG BUY
WSX Forecast (1yr):
25.10%
Analyst Rating:
STRONG BUY
Analyst Forecast (1yr):
62.40%

TARS Stock Analysis

TARS PE Ratio:

TARS PEG Ratio: Not Available

TARS Forward EPS Growth (12 month): 0.00%

TARS PS Ratio: 4.7

TARS PSG Ratio: 0.2

TARS Forward Revenue Growth (12 month): 30.20%

TARS Articles

No data was found